mn(iii) 5,10,15,20-tetrakis(n-methylpyridinium-2-yl)porphyrin has been researched along with ascorbic acid in 3 studies
| Studies (mn(iii) 5,10,15,20-tetrakis(n-methylpyridinium-2-yl)porphyrin) | Trials (mn(iii) 5,10,15,20-tetrakis(n-methylpyridinium-2-yl)porphyrin) | Recent Studies (post-2010) (mn(iii) 5,10,15,20-tetrakis(n-methylpyridinium-2-yl)porphyrin) | Studies (ascorbic acid) | Trials (ascorbic acid) | Recent Studies (post-2010) (ascorbic acid) |
|---|---|---|---|---|---|
| 69 | 0 | 42 | 45,261 | 2,497 | 11,176 |
| Protein | Taxonomy | mn(iii) 5,10,15,20-tetrakis(n-methylpyridinium-2-yl)porphyrin (IC50) | ascorbic acid (IC50) |
|---|---|---|---|
| Chain A, Hyaluronidase, phage associated | Streptococcus pyogenes | 1000 | |
| Urease | Canavalia ensiformis (jack bean) | 8.59 | |
| Solute carrier family 23 member 1 | Homo sapiens (human) | 156 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Knox, SJ; Peehl, DM; Tian, J | 1 |
| Batinic-Haberle, I; Derrick, M; Drobyshevsky, A; Du, H; Luo, K; Prasad, PV; Tan, S; Vasquez-Vivar, J; Yu, L | 1 |
| Avenoso, A; Calatroni, A; Campo, GM; Campo, S; D'Ascola, A; Micali, A; Nastasi, G; Pisani, A; Puzzolo, D; Scuruchi, M | 1 |
3 other study(ies) available for mn(iii) 5,10,15,20-tetrakis(n-methylpyridinium-2-yl)porphyrin and ascorbic acid
| Article | Year |
|---|---|
Metalloporphyrin synergizes with ascorbic acid to inhibit cancer cell growth through fenton chemistry.
Topics: Antioxidants; Apoptosis; Ascorbic Acid; Blotting, Western; Catalase; Cell Proliferation; Drug Synergism; Glutathione; Glutathione Reductase; Humans; Hydrogen Peroxide; Hydroxyl Radical; Liver Neoplasms; Male; Manganese; Membrane Potential, Mitochondrial; Metalloporphyrins; Neoplasms, Hormone-Dependent; Oxidation-Reduction; Pancreatic Neoplasms; Prostatic Neoplasms; Reactive Oxygen Species; Superoxides; Tumor Cells, Cultured | 2010 |
Motor deficits are triggered by reperfusion-reoxygenation injury as diagnosed by MRI and by a mechanism involving oxidants.
Topics: Age Factors; Animals; Animals, Newborn; Antioxidants; Ascorbic Acid; Benzimidazoles; Blood Flow Velocity; Brain; Brain Mapping; Carbocyanines; Chromans; Diffusion Magnetic Resonance Imaging; Disease Models, Animal; Embryo, Mammalian; Female; Flow Cytometry; Hypoxia-Ischemia, Brain; Ionophores; Laser-Doppler Flowmetry; Membrane Potential, Mitochondrial; Metalloporphyrins; Microvessels; Mitochondria; Movement Disorders; Muscle Hypertonia; O Antigens; Pregnancy; Rabbits; Reperfusion Injury; Superoxides; Time Factors; Valinomycin | 2012 |
The SOD mimic MnTM-2-PyP(5+) reduces hyaluronan degradation-induced inflammation in mouse articular chondrocytes stimulated with Fe (II) plus ascorbate.
Topics: Animals; Ascorbic Acid; Cartilage, Articular; Chondrocytes; Cysteamine; Gene Expression Regulation; Hyaluronan Receptors; Hyaluronic Acid; Inflammation; Interleukin-1beta; Iron; Lipid Peroxidation; Male; Matrix Metalloproteinase 13; Metalloporphyrins; Mice; Molecular Weight; NF-kappa B; Nitric Oxide Synthase Type II; Oxidation-Reduction; Peptides; Reactive Oxygen Species; RNA, Messenger; Superoxide Dismutase; Toll-Like Receptor 2; Toll-Like Receptor 4; Tumor Necrosis Factor-alpha | 2013 |